Pontine μ‐opioid receptors mediate the bradypnea caused by clinically relevant rates of intravenous remifentanil in dogs (CROSBI ID 719379)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Prkic, Ivana ; Mustapic, Sanda ; Radocaj, Tomislav ; Stucke, Astrid G. ; Stuth, Eckehard A. ; Hopp, Francis A. ; Dean, Caron ; Zuperku, Edward J.
engleski
Pontine μ‐opioid receptors mediate the bradypnea caused by clinically relevant rates of intravenous remifentanil in dogs
Life-threatening side effects such as profound bradypnea or apnea and variable upper airway obstruction limit the use of opioids for analgesia. It is yet unclear which sites containing mu-opioid receptors (MORs) within the respiratory control network are responsible. The purpose of this study was 1) to define the pontine region in which MOR agonists produce bradypnea and 2) to determine whether antagonism of those MORs reverses bradypnea produced by IV remifentanil (remi ; 0.1–1.0 μg/kg/min). The effects of microinjections of agonist [D-Ala2, N-Me-Phe4, Gly-ol5]-enkephalin (DAMGO ; 100 μM) and antagonist naloxone (NAL ; 100 μM) into the dorsal rostral pons on the phrenic neurogram were studied in a decerebrate, vagotomized, ventilated, paralyzed canine preparation during hyperoxia. A 1-mm grid pattern of microinjections was used. The DAMGO sensitive region extended from 5–7 mm lateral of midline and from 0–2 mm caudal of the inferior colliculus at a depth of 3–4 mm. During remi- induced bradypnea (71.5±3.6% reduction in breathing rate ; 21 dogs) NAL microinjections (860±69 nl each) within the region defined by the DAMGO protocol were able to reverse bradypnea (47.2±5.2%/injection) with 13 of 84 injections producing complete reversal. Histological examination of dye injections shows that the sensitive region corresponds to the parabrachial Kölliker-Fuse complex. Supported by VA Medical Research Funds.
mu-opioid receptors ; respiratory control network ; parabrachial Kölliker-Fuse complex
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
1088.10
2012.
objavljeno
10.1096/fasebj.26.1_supplement.1088.10
Podaci o matičnoj publikaciji
John Wiley & Sons
0892-6638
Podaci o skupu
Experimental Biology 2012
poster
21.04.2012-25.04.2012
San Diego (CA), Sjedinjene Američke Države
Povezanost rada
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)